The mission of the Vaccinology Core at LMIV is to address the global need for a malaria vaccine by focusing fundamental and clinical research in malaria immunobiology and vaccinology. BSAM2/Alhydrogel+CPG 7909, a vaccine candidate comprised of AMA1-FVO, AMA1-3D7, MSP142-FVO and MSP142-3D7 in equal mass ratio, has been evaluated in a Phase 1 trial in US. Following safety evaluation of the vaccine in US volunteers, the vaccine candidate is being evaluated in adults in a Phase 1b trial in Mali. The vaccine is well tolerated, whereas the immunogenicity and correlation between antibody titers and the in vitro growth inhibitory activities are being analyzed.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2012
Total Cost
$403,341
Indirect Cost
City
State
Country
Zip Code